Skip to main content
Log in

18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the interest of 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) for diagnosis and therapeutic follow-up of patients with sarcoidosis.

Methods

Twenty consecutive patients with biopsy-proven sarcoidosis were retrospectively included, in particular, 13 and seven cases of thoracic and extra-thoracic sarcoidosis, respectively. All patients underwent 18F-FDG PET/CT, and 12 of them also 67Ga scintigraphy. Five patients were re-examined by 18F-FDG PET/CT to assess response to corticosteroid (CS) treatment.

Results

Sensitivity of 18F-FDG PET/CT in detecting active sarcoidosis localizations was determined considering only biopsy-proven sites. For thoracic, sinonasal, and pharyngo-laryngeal localizations, 18F-FDG PET/CT sensitivity was 100%, 100%, and 80%, respectively. Overall sensitivity for all 36 biopsy-proven localizations improved from 78% to 87% after excluding skin involvement. Considering only the 12 patients who underwent both scintigraphic examinations, overall sensitivity of 67Ga scintigraphy and 18F-FDG PET/CT was 58% and 79%, respectively and improved to 67% and 86% after excluding all sites of skin involvement. To evaluate the efficacy of CS treatment, five enrolled patients underwent second 18F-FDG PET/CT. Complete regression of all foci of pathological tracer uptake was showed in two cases, permitting CS withdrawal after 2 and 6 months. Improvement but incomplete regression of mediastino-pulmonary disease occurred in two patients treated with CS for 19 and 21 months. Disease progression was assessed in one patient treated with decreasing doses of CS during 16 months.

Conclusion

18F-FDG PET/CT allows to obtain a complete morpho-functional cartography of inflammatory active localizations and to follow treatment efficacy in patients with sarcoidosis, particularly in atypical, complex, and multisystemic forms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–8.

    Article  PubMed  CAS  Google Scholar 

  2. Schwartzbauer HR, Tami TA. Ear, nose and throat manifestations of sarcoidosis. Otolaryngol Clin N Am. 2003;36:673–84.

    Article  Google Scholar 

  3. Braun JJ, Gentine A, Pauli G. Sinonasal sarcoidosis: review and report of fifteen cases. Laryngoscope. 2004;114:1960–3.

    Article  PubMed  Google Scholar 

  4. Aubart FM, Ouayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, et al. Sinonasal involvement in sarcoidosis. Medicine. 2006;85:365–71.

    Article  PubMed  Google Scholar 

  5. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S.

    PubMed  CAS  Google Scholar 

  6. Teirstein AS, Machac J, Almeida O, Lu P, Padilla M, Iannuzzic MC. Results of 188 whole-body FDG PET scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.

    Article  PubMed  Google Scholar 

  7. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48:35–45.

    PubMed  CAS  Google Scholar 

  8. Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med. 2007;32:114–6.

    Article  PubMed  Google Scholar 

  9. Nguyen BD. F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med. 2007;32:53–4.

    Article  PubMed  Google Scholar 

  10. Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–6.

    PubMed  Google Scholar 

  11. Klech H, Kohn H, Kummer F, Mostbeck A. Assessment of activity in sarcoidosis. Chest. 1982;82:732–8.

    Article  PubMed  CAS  Google Scholar 

  12. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in non malignant thoracic disorders. Semin Nucl Med. 2002;32:293–321.

    Article  PubMed  Google Scholar 

  13. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis. J Nucl Med. 1994;35:1650–2.

    PubMed  CAS  Google Scholar 

  14. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305.

    Article  PubMed  CAS  Google Scholar 

  15. Alavi A, Palevsky HI. Gallium-67-citrate scanning in the assessment of disease activity in sarcoidosis. J Nucl Med. 1992;33:751–5.

    PubMed  CAS  Google Scholar 

  16. Baughman RP, Fernandez M, Bosken CH, Mantil J, Hurtubise P. Comparison of gallium-67 scanning, bronchoalveolar lavage and serum angiotensin–converting enzyme levels in pulmonary sarcoidosis: predicting response to therapy. Am Rev Respir Dis. 1984;129:676–81.

    PubMed  CAS  Google Scholar 

  17. Lawrence EC, Teague RB, Gottlieb MS, Jhingran SG, Lieberman J. Serial changes in markers of disease activity with corticosteroid treatment in sarcoidosis. Am J Med. 1983;74:747–56.

    Article  PubMed  CAS  Google Scholar 

  18. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34:313–29.

    Article  PubMed  Google Scholar 

  19. Koyama T, Ueda H, Togashi K, Umeoka S, Kataoka M, Nagai S. Radiologic manifestations of sarcoidosis in various organs. RadioGraphics. 2004;24:87–104.

    Article  PubMed  Google Scholar 

  20. Loehrl TA, Smith TL. Inflammatory and granulomatous lesions of the larynx and pharynx. Am J Med. 2001;111:113–7.

    Article  Google Scholar 

  21. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. RadioGraphics. 2005;25:1357–68.

    Article  PubMed  Google Scholar 

  22. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–69.

    Article  PubMed  Google Scholar 

  23. Xiu Y, Yu JQ, Cheng A, Kumar R, Alavi A, Zhunang H. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med. 2005;30:193–5.

    Article  PubMed  Google Scholar 

  24. Vento JA, Arici M, Spencer RP, Sood R. F-18 FDG PET: mottled splenomegaly with remission of symptoms after splenectomy in sarcoidosis. Clin Nucl Med. 2004;29:103–4.

    Article  PubMed  Google Scholar 

  25. Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, et al. Diagnostic usefulness of fluorine-18-a-methyltyrosine positron emission tomography in combination with F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019–27.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alessio Imperiale.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braun, J.J., Kessler, R., Constantinesco, A. et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 35, 1537–1543 (2008). https://doi.org/10.1007/s00259-008-0770-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-008-0770-9

Keywords

Navigation